- Home
- ERAS vs TALK Comparison
ERAS vs TALK Comparison
Compare ERAS & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- TALK
- Stock Information
- Founded
- ERAS 2018
- TALK 2012
- Country
- ERAS United States
- TALK United States
- Employees
- ERAS N/A
- TALK N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- TALK Medical/Nursing Services
- Sector
- ERAS Health Care
- TALK Health Care
- Exchange
- ERAS Nasdaq
- TALK Nasdaq
- Market Cap
- ERAS 439.7M
- TALK 442.1M
- IPO Year
- ERAS 2021
- TALK N/A
- Fundamental
- Price
- ERAS $2.32
- TALK $2.83
- Analyst Decision
- ERAS Buy
- TALK Buy
- Analyst Count
- ERAS 6
- TALK 6
- Target Price
- ERAS $3.83
- TALK $4.50
- AVG Volume (30 Days)
- ERAS 1.7M
- TALK 1.0M
- Earning Date
- ERAS 11-11-2025
- TALK 10-28-2025
- Dividend Yield
- ERAS N/A
- TALK N/A
- EPS Growth
- ERAS N/A
- TALK N/A
- EPS
- ERAS N/A
- TALK 0.02
- Revenue
- ERAS N/A
- TALK $202,611,000.00
- Revenue This Year
- ERAS N/A
- TALK $22.35
- Revenue Next Year
- ERAS N/A
- TALK $21.66
- P/E Ratio
- ERAS N/A
- TALK $166.40
- Revenue Growth
- ERAS N/A
- TALK 17.43
- 52 Week Low
- ERAS $1.01
- TALK $2.22
- 52 Week High
- ERAS $3.31
- TALK $4.36
- Technical
- Relative Strength Index (RSI)
- ERAS 68.53
- TALK 62.88
- Support Level
- ERAS $1.78
- TALK $2.66
- Resistance Level
- ERAS $2.65
- TALK $2.86
- Average True Range (ATR)
- ERAS 0.20
- TALK 0.11
- MACD
- ERAS 0.05
- TALK 0.02
- Stochastic Oscillator
- ERAS 68.34
- TALK 76.19
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.